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Since treatment of active disease remains the priority for tuberculosis control, donors and governments need to be convinced
that investing resources in chemoprophylaxis provides health benefits and is good value for money. The limited evidence of cost
eﬀectiveness has often been presented in a fragmentary and inconsistent fashion. Objective. This review is aimed at critically
reviewing the evidence of cost eﬀectiveness of chemoprophylaxis against tuberculosis, identifying the important knowledge gaps
and the current issues which confront policy makers. Methods. A systematic search on economic evaluations for chemoprophylaxis
against tuberculosis was carried out, and the selected studies were checked for quality assessment against a standard checklist.
Results. The review provides evidence of the cost eﬀectiveness of chemoprophylaxis for all age groups which suggests that current
policy should be amended to include a focus on older adults. Seven of the eight selected studies were undertaken wholly in high
income countries but there are considerable doubts about the transferability of the findings of the selected studies to low and
middle income countries which have the greatest incidence of latent tuberculosis infection. Conclusion. There is a pressing need to
expand the evidence base to low and middle income countries where the vast majority of suﬀerers from tuberculosis live.
1. Background
Tuberculosis (TB) is a leading cause of morbidity and mor-
tality worldwide. Two million people a year die of tuberculo-
sis, making it the single leading microbial killer of adults [1].
The vast majority of cases occur in low and middle income
countries. In 2008, the WHO regions of Europe and the
Americas accounted for only 8% of the global number of
incident cases [2].
A further threat is latent tuberculosis infection (LTBI) in
which there is the risk of developing active disease. The cur-
rent recommended standard chemoprophylaxis therapy for
LTBI prevention is 9 months of isoniazid (9INH) which has
an eﬃcacy of more than 90% if taken properly [3, 4]. Iso-
niazid preventive therapy (IPT) has a greater protective eﬀect
on childhood TB, reducing the chance of developing pro-
bable or definite TB by 72% [5].
Since treatment of active disease remains the priority for
TB control, donors and governments need to be convinced
that investing resources in chemoprophylaxis provides health
benefits and is good value for money. However, most studies
focus on high income settings, and there is uncertainty of
whether similar eﬀects can be expected in low andmiddle in-
come countries where the severity of the problem is diﬀerent.
There is accumulated evidence of the individual [6, 7]
and public health [8] benefits of chemoprophylaxis in high
income settings, but very few studies of its cost eﬀectiveness.
The limited evidence of the cost eﬀectiveness of preventive
measures against TB is often presented in a fragmentary and
inconsistent fashion [9]. This review is aimed at critically
reviewing the evidence of cost eﬀectiveness of chemoprophy-
laxis against TB, identifying the important knowledge gaps
and the current issues which confront policy makers.
2. Methods
2.1. Literature Search. A systematic search on economic eval-
uations for chemoprophylaxis against TB was carried out in
July 2010, by the first named author, on the following
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Potentially relevant studies
identified and screened for
retrieval (n = 238)
Studies excluded due to lack of data on cost and chosen
eﬀectiveness outcomes (n = 205)
Studies retrieved for more
detailed evaluation (n = 33)
Studies included (n = 8)
Studies excluded due to emphasis on specific population
groups (n = 25)
(a) HIV-infected population (n = 9)
(b) Group of immigrants (n = 7)
(c) Health professionals (n = 3)
(d) Drug injectors (n = 2)
(e) Systematic lupus erythematosis (n = 1)
(f) Population in correction facility (n = 1)
(g) Prophylaxis in antepartum or postpartum period (n = 1)
(h) Integration with methadone maintenance clinic (n = 1)
Studies included (n = 8)
Figure 1: Flow chart of study selection process.
databases: EMBASE (1980–2010), using keywords “econo-
mic evaluation,” “cost,” “cost-eﬀectiveness,” “chemoprophy-
laxis,” and “tuberculosis”; NHS EED, HRD, and HEED (CRD
database: http://www.crd.york.ac.uk/crdweb/), using key-
words “tuberculosis,” “prevention,” and “cost”; MEDLINE
(1950–2010), using 30 diﬀerent search terms. The bibliogra-
phies of available papers were checked for any additional rele-
vant studies.
2.2. Inclusion Criteria. Studies eligible for inclusion were
economic evaluations of chemoprophylaxis against TB.
There were no restrictions on the drug type or duration of
therapy. The intervention could be directly observed treat-
ment, which is under supervision, or self-administered treat-
ment. There were no restrictions on the age and sex of study
populations or on the types of study design, cost analysis, and
perspective of economic evaluations. Non-English studies
were excluded.
The outcomes included (when available) were the incre-
mental cost-eﬀectiveness ratio (ICER) for cost per life year
saved, number of TB cases and TB related deaths, number
needed to treat (NNT) to prevent one TB case, number
of drug-induced hepatic toxicity incidents, the endpoint of
withdrawals due to toxicity, and lack of patient compliance.
Searches for economic evidence on chemoprophylaxis
against TB yielded a total of 238 published articles. After ex-
clusion and hand searches, 33 economic studies relevant to
the review topic were identified. However, many of these
studies were concerned with specific groups such as HIV-
positive people, immigrants, drug injectors, prisoners, and
health professionals. Since results derived from such studies
cannot be applied to the general population, they were ex-
cluded from the final selection. Although this review did not
include economic and societal benefits of prevention of TB in
HIV patients, countries with high incidence of HIV and TB,
use of IPT along with ART should be highly cost eﬀective.
The study selection process is summarized in Figure 1.
Eight economic evaluation studies of chemoprophylaxis
against TB [11–18] were included in this systematic review,
summarized in Table 1.
2.3. Quality Assessment. The selected studies were assessed
against a standard checklist of best practice in economic
evaluation. This checklist consists of ten questions covering
such issues as evidence of eﬀectiveness, the careful mea-
surement and valuation of costs and consequences, and
allowance for uncertainty [19]. The scoring tool is similar
to QUADAS and other such methodology checklists. Studies
were scored 1 for each “yes” answer, 0 for “no,” and 0.5
for “partially.” Initial scoring was done by the first two
named authors independently of one another with almost
complete agreement. Subsequent discussion led to the swift
achievement of total consensus. The eight studies are scored
against this checklist in Table 2.
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Table 1: Summary of selected studies.
(a)
Study objective Study population and setting
Rose et al. [11]
To compare TB prevention with isoniazid (INH)
chemoprophylaxis to no intervention, for low risk as
well as high-risk tuberculin reactors
Men aged 20, recently infected with tubercle bacillus
and thus at high risk; men aged 55, older tuberculin
reactors having low risk of activation US
Salpeter et al.
[12]
To evaluate the eﬀectiveness and cost eﬀectiveness of
monitored INH prophylaxis for low-risk tuberculin
reactors older than 35 years of age
35, 50 and 70-year-old low risk tuberculin reactors
who have normal chest radiograph and are not at
increased risk of tuberculin activation US
Jasmer et al.
[13]
To determine cost eﬀectiveness of
rifampin-pyrazinamide (RZ) for 2 months
compared with INH for 6 months for treatment of
latent tuberculosis in adults without HIV infection
Adult aged 17 years or older with a tuberculin skin
test result, in whom active TB is excluded and in
whom treatment of latent TB infection would
ordinarily be recommended; exclusion criteria are
pregnancy, HIV infection, and history of gout US
Diel et al. [14]
To perform a cost-eﬀectiveness analysis in
young-and middle-aged adults with latent
tuberculosis infection
20- and 40-year old close contacts of active TB cases
with positive Mantoux test and in whom active TB is
excluded Germany
Holland et al.
[15]
To evaluate cost and cost eﬀectiveness of diﬀerent
regimens for treatment of LTBI
Hypothetical cohort of individuals with LTBI
contacts of infectious case, all adults with average
age of 39 years US
Tan et al. [16]
To evaluate cost eﬀectiveness of LTBI therapy for
diﬀerent TB contact population defined by
important risk factors and to propose optimal policy
based on diﬀerent recommendations for each
subgroup of contact
TB contacts with tuberculin test size ≥5mm, defined
by age group (<10 y/o or above), ethnicity
(Canadian born/foreign born), BCG vaccination
status British Columbia, Canada
Fitzgerald and
Gafni [17]
To evaluate role of INH prophylaxis in low-risk
patients with positive Mantoux test result and
identify most eﬃcient use of health care resources
20-, 50-, and 70-years-old low-risk patients with
positive Mantoux test Canada
Ziakas and
Mylonakis [18]
To compare eﬃcacy, toxicity, and cost of the
4-month Rifampin treatment (4RIF) with the
standard 9-month INH strategy (9INH) from
pooled meta-analysis of published clinical studies
Patient-related data from eight Canadian centres,
two US centres, one Saudi Arabian centre, and one
Brazilian centre
(b)
Measure of outcomes Cost eﬀectiveness Implications
Rose et al. [11]
Life years gained,
quality-adjusted life years
(QALYs)
Incremental cost eﬀectiveness
ratio (ICER)
For high-risk reactors over 35,
isoniazid dominates no intervention;
cost savings and greater benefits
(increased life expectancy).
For low-risk reactors over 35, ICER of
isoniazid over no intervention of
$12,625 per year of life gained and
$35,011 per death averted
Study can contribute to a
change in existing policy and
practice; consideration of INH
therapy for all infected persons
irrespective of age group and
risk of tuberculin reactors
Salpeter et al. [12]
Number needed to treat,
life years gained, and probability
of survival at 1-year
Cost saving
Isoniazid dominates no intervention
for 35, 50 and 70 year olds; cost
savings and increased life expectancy
Study can contribute to a
change in existing policy and
practice; consideration of all
age groups for preventive
therapy leading to potential
public health benefits
Jasmer et al. [13]
Number of TB cases averted,
number of TB-related deaths
ICER
Isoniazid dominates no intervention;
cost savings and increased life
expectancy, more deaths prevented
Isoniazid costs less than
rifampin-pyrazinamide; both
treatments have the same gain in life
expectancy
ICER of rifampin over no intervention
of $2,494 per case prevented
Justify existing policy of INH
prophylaxis
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(b) Continued.
Measure of outcomes Cost eﬀectiveness Implications
Diel et al. [14]
Number needed to treat, number
of TB-related deaths avoided
Cost saving
Isoniazid dominates no intervention
for 20 and 40 year olds; cost savings,
more cases, and TB-related deaths
prevented
Acceleration of expansion of
INH prevention
Holland et al. [15]
Life years gained,
QALYs
ICER
Rifampin dominates
(self-administered and, directly
observed) isoniazid; cost savings and
more QALYs gained, more cases of
active TB-prevented
ICER of isoniazid-rifapentine over
rifampinof $48,999 per QALY gained
Study can contribute to a
change in existing policy and
practice; highlights important
knowledge gaps
Tan et al. [16]
Number of active TB cases
prevented, QALYs
Net monetary benefit
Test and treat (with isoniazid) more
cost eﬀective (in terms of net
monetary benefit, the diﬀerence
between benefits, valued at $50,000 per
QALY, and costs) than no screening
and treat all, for most subgroups
Justifies existing policy; support
current practice of provision of
treatment on the basis of TST
size; exclusion of low-risk
groups from screening and
providing treatment to
high-risk contacts without
screening could improve the
performance of the program
Fitzgerald and
Gafni [17]
Number of TB cases prevented,
life years gained
Direct as well as indirect costs in
diﬀerent age groups
Average cost per case prevented in
low-risk patients by isoniazid of $8,586
(20-year old), $28,260 (50 year old),
and $40,102 (70-year old)
Justifies existing policy of INH
prophylaxis; considers of all age
groups; highlights importance
of including indirect as well as
direct costs
Ziakas and
Mylonakis [18]
Hepatotoxicity, compliance
Cost saving
Rifampin dominates isoniazid; cost
savings and lower risk of
noncompletion, lower rate of
hepatotoxicity
Justifies existing policy; 9INH
therapy is considered as
standard of care
3. Results
3.1. Result of Quality Assessment. All bar two, Fitzgerald and
Gafni [17] and Ziakas and Mylonakis [18], scored very well,
with a total of 9 or 9.5 out of 10.
In addition, although the final question of the checklist
concerns “issues of concern to users” of the economic evalua-
tion results, it is increasingly common to separately consider
the ease of transferability of the results to other contexts [20].
Transferability depends on similarities in demographic and
epidemiological characteristics but also the health system
structures necessary to deliver treatment eﬀectively. Trans-
ferability is likely therefore to be strong between high income
contexts like Germany, the US, and Canada, countries cover-
ed in the selected studies, but not from high income con-
texts to low and middle income countries. Indeed, all the
selected studies performed equally well in terms of their
transferability to other high income countries, apart from
Tan et al. [16]. This study is based on data on subgroups from
British Columbia which would be diﬃcult to transfer to
other settings.
In summary, five studies [7, 11–15] scored well, both in
terms of the best practice checklist and the transferability of
results to other (high income) countries.
3.2. Cost-Eﬀectiveness Results. Isoniazid dominates no inter-
vention, whichmeans it costs less and provides greater health
benefits, for all groups [7, 12–14] or high risk groups [11].
In turn, two studies find that rifampin dominates isoniazid
[15, 18].
Only three studies presented incremental cost-eﬀective-
ness ratio (ICER) results but none are comparable, one being
the ICER of isoniazid over no intervention, for low risk
groups [11], the second rifampin over no intervention [7,
13], and the third isoniazid-rifapentine over rifampin [15].
However, for what it is worth, the ICER values reported are
all reasonable, implying that each first named (more expen-
sive) treatment is cost eﬀective. Meta-analysis was not con-
sidered because of the heterogeneity of the studies. The
eﬀectivenessmeasures diﬀer among studies, as do the curren-
cy and cost year.
4. Discussion
4.1. Age. Due to increased risk of isoniazid induced hepato-
toxicity, American Thoracic Society in 1974 restricted the
use of isoniazid prophylaxis to low-risk tuberculin reactors
older than 35 years of age. But revised 1983 guidelines recom-
mended clinicians to evaluate andmonitor liver function and
discontinue treatment if aminotransferase levels exceed 3–5
times normal values [3]. The majority of the selected studies
found evidence of the cost eﬀectiveness of chemoprophylaxis
for people over 35-year old which suggests that current
policy should be amended to include a focus on older adults.
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Table 2: Checklist of best practice in economic evaluation studies.
Rose Salpeter Jasmer Diel Holland Fitzgerald Tan Ziakas
(1) Was a well-defined question
posed in answerable form?
1 1 1 1 1 0.5 1 1
(2) Was a comprehensive
description of the competing
alternatives given?
1 1 1 1 1 1 1 1
(3) Was the eﬀectiveness of the
programme or services
established?
1 1 1 1 1 1 1 1
(4) Were all the important and
relevant costs and consequences
for each alternative identified?
0.5 0.5 0.5 1 1 0.5 1 0.5
(5) Were costs and consequences
measured accurately in
appropriate physical units?
1 1 1 1 1 1 1 0.5
(6) Were the costs and
consequences valued credibly?
1 1 0.5 1 1 0.5 1 1
(7) Were costs and consequences
adjusted for diﬀerential timing?
1 1 1 1 1 0.5 1 0.5
(8) Was an incremental analysis
of costs and consequences of
alternatives performed?
1 1 1 1 1 0 1 1
(9) Was allowance made for
uncertainty in the estimates of
costs and consequences?
1 1 1 1 1 1 1 1
(10) Did the presentation and
discussion of results include all
issues of concern to users?
0.5 0.5 1 0.5 0.5 0.5 0.5 0.5
Total 9 9 9 9.5 9.5 6.5 9.5 8
A further study [21] confirmed the health benefits of INH
prophylaxis to all age groups, apart from those aged over 80.
Such results might help practitioners to implement current
guidelines without fear of hepatotoxicity.
Among children, Tan et al. [16] found that direct imple-
mentation of preventive treatment of non-BCG-vaccinated
household contacts of less than 10-year old is justified.
4.2. Diﬀerent Drug Regimens for Prophylaxis. Holland et al.
[15] found that the 4-month rifampin approach was associ-
ated with significant lifelong cost savings for most programs
in the US and Canada although the results did not include
information on compliance and hepatotoxicity. Jasmer et al.
[13] show that, in spite of the shorter duration of the
2-month treatment with rifampin-pyrazinamide (RZ), the
associated high cost of routine laboratory monitoring for sig-
nificant higher-risk hepatotoxicity and hospitalization made
it less cost eﬀective than 6-month isoniazid treatment. Re-
garding 4-month rifampin, one study [22] found that patient
acceptance and compliance is excellent but argued for further
research on its safety and eﬃcacy. Ziakas and Mylonakis [18]
also found evidence of the superiority of 4-month Rifam-
pin compared to 9-month INH therapy in terms of safety,
compliance, and cost.
4.3. Drug-Induced Hepatotoxicity. A 1983 revision of guide-
lines issued by the American Thoracic Society recommended
clinicians to evaluate and monitor liver function and discon-
tinue treatment if aminotransferase levels exceed 3–5 times
normal values [23]. Two studies of monitored prophylaxis
based upon these revised guidelines [24, 25] found very
low mortality rates, of about 0.001%, similar to the rate of
death from acute hepatitis and acute liver necrosis from any
cause in the general population. Salpeter et al. [12] conclude
that monitored isoniazid prophylaxis should be extended to
tuberculin reactors of all ages.
4.4. Transferability. Seven of the eight selected studies were
undertaken in high income countries: four in the US, two in
Canada, and one in Germany. All these studies used cost data
and life tables from country databases. The eighth study was
a pooled meta-analysis which used US cost data and patient-
related data from eight Canadian centers, twoUS centers, one
Saudi Arabian centre, and one Brazilian centre.
Clearly, the selected studies have most relevance to high
income countries, precisely those which have the lowest bur-
den of TB. However, the results, particularly those that relate
to cost eﬀectiveness, are diﬃcult to transfer to diﬀerent sett-
ings. The level and structure of costs of treatment of LTBI dif-
fer considerably across the world. The prices of drugs, which
are internationally traded, will not generally vary much, but
prices of local goods and services, such as the salaries of
health professionals or transport costs, can vary enormously.
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While the prices of drugs may not diﬀer much, their avail-
ability and quality can vary. There may be considerable eco-
nomies of scale. The cost per TB case prevented will often
diminish rapidly as the number of cases prevented increas-
es—assuming that the appropriate infrastructure is in place
to treat a greater number of cases [26].
While the greatest diﬀerencesmay lie with such economic
factors, countries also vary with regard to their organiza-
tional structures which influence their capacity to screen,
treat, and monitor patients on a regular basis [27]. More
broadly, countries diﬀer in their demographic and epidemio-
logical characteristics and in treatment compliance rates. As a
result of all these factors, there are considerable doubts about
the transferability of the findings of the eight selected studies
to low and middle income countries which have the greatest
incidence of LTBI.
4.5. Research and Policy Implications. The eight selected stud-
ies, particularly the five which score well on all measures of
quality assessment [11–15], provide robust evidence of the
eﬀectiveness and cost eﬀectiveness of preventive TB treat-
ment in high income countries. However, there is an urgent
research need to produce evidence for low and middle in-
come countries. For example, not even the World Health Or-
ganisation (WHO) provides comprehensive guidelines for
preventive therapy [28]. It would be a very slow and costly
process to replicate the type of careful analyses conducted in
the selected studies in this paper in every country in which
decisions have to be made about the allocation of scarce
health care resources to TB treatment and prevention. In-
stead, population and decision modeling techniques can be
employed. WHO-CHOICE, developed by the World Health
Organization (WHO), is an attempt to provide relevant
information on health eﬀects and cost structures at a regional
level which can then be adapted to the country level by the
use of national data [29].
In policy terms, the priority use of scarce resources in
some low and middle income countries may still be treat-
ment of active rather than latent cases of TB. However, for
those countries which are able to expand their preventive
programmes, the implications of the selected studies for pol-
icy and practice are summarized in Table 1. For high income
countries at least, the current recommendation of use of iso-
niazid for 9 months is cost eﬀective (as compared to no pro-
phylaxis). It yields significant health and cost benefits. How-
ever, policy makers need to consider expanding treatment to
cover all age groups, so long as therapy is monitored. Moni-
toring during therapy increases the cost of care in the short
run. But it leads to better compliance and a reduction in sec-
ondary transmission with consequent benefits in long term.
In global terms, growing evidence of the eﬀectiveness and
cost eﬀectiveness of preventive treatment of TB could help
mobilize donor funding [10] to invest in the development of
evidence for a programme for chemoprophylaxis in low and
middle income countries.
5. Conclusion
The studies selected in this paper provide clear evidence of
the health benefits and cost eﬀectiveness of chemoprophy-
laxis for TB, but this evidence is derived almost totally from
three high income countries: the US, Canada, and Germany.
There are great variations in terms of economic factors,
organisational structure, and epidemiological characteristics
between nonendemic and endemic countries. In the former,
the transmission of disease is well controlled and the chance
of experiencing TB infection is lower. The impact of pre-
ventive therapy in low risk settings cannot be extrapolated to
TB endemic countries where the eﬀect of preventive therapy
could be transient. We argue that there is a pressing need to
expand the evidence base to low and middle income coun-
tries where the vast majority of suﬀerers from TB live. The
fight against TB calls for an increase emphasis on prevention
for the most vulnerable groups.
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